RxDoctor Payments Data

Amanda du Sablon, DO

Family Medicine · Lenoir, NCNPI 1851701593

Payments from drug & device makers

$8,731in general payments, 2019–2025

Across 545 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$927
  • Pfizer$897
  • AstraZeneca$851
  • Lilly USA, LLC$773
  • GSK$556
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$8,60098%
  • Education$1312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,731 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$55,930
Medicare patients
154
Services billed
912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide118$147,480
EliquisApixaban61$65,752
FarxigaDapagliflozin Propanediol42$39,111
RybelsusSemaglutide23$33,317
JardianceEmpagliflozin21$27,362
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$26,671
TrulicityDulaglutide28$26,413
MounjaroTirzepatide25$26,282
LinzessLinaclotide20$25,343
VraylarCariprazine Hcl12$19,924
MyrbetriqMirabegron18$16,094
Tresiba Flextouch U-100Insulin Degludec26$13,024
Breo ElliptaFluticasone/Vilanterol27$10,553
Repatha SureclickEvolocumab18$9,520
Gabapentin275$4,963

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$927$180,797141 claims
AstraZenecaFarxiga, Breztri Aerosphere$851$65,78281 claims
PfizerEliquis$897$65,75261 claims
Lilly USA, LLCTrulicity, Mounjaro$773$52,69653 claims
AbbVieLinzess, Vraylar, Synthroid$1,774$48,47260 claims
Boehringer IngelheimJardiance$47$27,36221 claims
Astellas Pharma US IncMyrbetriq$197$16,09418 claims
GSKBreo Ellipta$556$10,55327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Lenoir

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →